Robotic surgery from miles away: could remote operations match On-Site care?

NCT ID NCT07716423

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This trial tests whether remote robotic surgery is as safe and effective as on-site robotic surgery for people needing liver, bile duct, gallbladder, or pancreas operations. In remote surgery, an expert surgeon controls the robot from a different location while the patient and local team are in the operating room. The study randomly assigns 168 adults to either remote or on-site robotic surgery and measures success rates, complications, and recovery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
remote robotic surgery
What this could lead to
If successful, this could show that remote robotic surgery is a safe and effective option, potentially expanding access to expert surgical care for patients in hospitals without specialized surgeons.
What could go wrong
This is a relatively small trial (168 patients) and technical issues like network delays or system failures could affect outcomes. Results may not apply to all types of surgeries or hospital settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 168 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jun 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 to 80 years, regardless of sex. * Scheduled to undergo robot-assisted hepatobiliary or pancreatic surgery, limited to hemihepatectomy, liver segmentectomy, local liver resection, cholecystectomy, pancreaticoduodenectomy, or distal pancreatectomy. * Considered to have an indication for surgery and to be suitable for robotic surgery based on preoperative assessment. * No definite contraindication to robotic surgery, laparoscopic surgery, pneumoperitoneum, or general anesthesia. * American Society of Anesthesiologists (ASA) physical status class I to III. * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2. * Expected survival of at least 3 months. * Adequate major organ function, with laboratory test results within 7 days before enrollment meeting the following criteria: white blood cell count at least 2.5 x 10\^9/L, absolute neutrophil count at least 1.5 x 10\^9/L, platelet count at least 75 x 10\^9/L, hemoglobin at least 90 g/L, international normalized ratio no more than 1.5 x upper limit of normal, and serum creatinine no more than 1.5 x upper limit of normal. * For patients undergoing liver surgery, Child-Pugh class A liver function or Child-Pugh class B liver function considered tolerable for surgery, with adequate liver reserve and adequate predicted future liver remnant volume. * For patients undergoing pancreatic surgery, imaging assessment showing resectability by robotic surgery without the need for complex vascular reconstruction. * Willing and able to complete perioperative observation and postoperative follow-up according to the study protocol. * Voluntarily agrees to participate in the study and provides written informed consent. Exclusion Criteria: * Need for combined vascular reconstruction. * Need for two or more major hepatobiliary or pancreatic procedures at the same time, or need for major resection of other organs. * Unable to complete full preoperative assessment, randomization, or remote robotic system preparation. * Considered clearly unsuitable for robotic surgery before the operation. * Preoperative assessment indicating a high probability of conversion to open surgery, or difficulty safely completing the planned procedure using a robotic platform. * Uncorrectable severe coagulation disorder or active bleeding tendency. * Severe dysfunction of the heart, lung, liver, kidney, brain, or other major organs that makes the patient unable to tolerate general anesthesia, pneumoperitoneum, or the planned surgery. * For patients undergoing liver surgery, inadequate liver reserve or inadequate predicted future liver remnant volume for safe surgery. * Uncontrolled severe infection, sepsis, severe malnutrition, or other conditions that significantly increase perioperative risk. * Pregnant or breastfeeding women. * Severe psychiatric, cognitive, or communication disorder that prevents cooperation with the study or follow-up. * Major compliance concerns as judged by the investigator. * Currently participating in another interventional clinical study that may affect endpoint assessment in this study. * Any other condition that, in the opinion of the investigator, makes the patient unsuitable for enrollment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatobiliary and pancreatic diseases are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.